

Principali pubblicazioni scientifiche Breast Unit AOU Careggi Firenze – 2019-2024 ^[1-131]

Direttore: Prof. Icro Meattini

Aggiornato al: 4 febbraio 2024

- [1] Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, et al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. *Lancet Oncol.* 2024;25:e73-e83.
- [2] Zampieri M, Schoonvelde SAC, Vinci M, Meattini I, Visani L, Fornaro A, et al. Cancer Treatment-Related Complications in Patients With Hypertrophic Cardiomyopathy. *Mayo Clin Proc.* 2024;99:218-28.
- [3] Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, et al. Essential requirements for reporting radiation therapy in breast cancer clinical trials: an international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). *Radiother Oncol.* 2023;110060.
- [4] Loibl S, Andre F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger). *Ann Oncol.* 2023.
- [5] Meattini I, Marta GN, Carroll S, Rivera S, Lamoury G, De Felice F, et al. Omission of radiation therapy after breast-conserving surgery for biologically favourable tumours in younger patients: The wrong answer to the right question. *Radiother Oncol.* 2023;190:110045.
- [6] Lambertini M, Blondeaux E, Agostinetti E, Hamy AS, Kim HJ, Di Meglio A, et al. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA.* 2024;331:49-59.
- [7] Shaitelman SF, Anderson BM, Arthur DW, Bazan JG, Bellon JR, Bradfield L, et al. Publisher's Note to Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline (Pract Radiat Oncol. 2024;14:xxx-xxx. Epub ahead of print November 14, 2023.). *Pract Radiat Oncol.* 2023.
- [8] Shaitelman SF, Anderson BM, Arthur DW, Bazan JG, Bellon JR, Bradfield L, et al. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline. *Pract Radiat Oncol.* 2023.
- [9] Kaidar-Person O, Tramm T, Kuehn T, Gentilini O, Prat A, Montay-Gruel P, et al. Optimising of axillary therapy in breast cancer: lessons from the past to plan for a better future. *Radiol Med.* 2023.
- [10] Marrazzo L, Redapi L, Pellegrini R, Voet P, Meattini I, Arilli C, et al. Fully automated volumetric modulated arc therapy technique for radiation therapy of locally advanced breast cancer. *Radiat Oncol.* 2023;18:176.
- [11] Giordano G, Griguolo G, Landriscina M, Meattini I, Carbone F, Leone A, et al. Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data. *Crit Rev Oncol Hematol.* 2023;192:104185.
- [12] Willmann J, Appelt AL, Balermipas P, Baumert BG, de Ruyscher D, Hoyer M, et al. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E(2)-RADlatE platform. *Radiother Oncol.* 2023;189:109947.
- [13] Leonardi MC, Pepa M, Zaffaroni M, Vincini MG, Luraschi R, Vigorito S, et al. Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy: An AIRO multi-institutional study. *Tumori.* 2023;109:570-5.

- [14] Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. *Ann Oncol.* 2023;34:970-86.
- [15] Banini M, Visani L, Livi L, Meattini I. De-escalating postoperative radiation therapy after primary systemic therapy in cT1-2N1 breast cancer: lesson from the RAPCHEM/BOOG 2010-03 trial. *Ann Transl Med.* 2023;11:366.
- [16] De Rose F, Colciago RR, Lucidi S, La Rocca E, Prisco A, Bonzano E, et al. Axillary Management in Breast Cancer Patients Undergoing Upfront Surgery: Results from a Nationwide Survey on Behalf of the Clinical Oncology Breast Cancer Group (COBCG) and the Breast Cancer Study Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). *Curr Oncol.* 2023;30:7489-98.
- [17] Francolini G, Garlatti P, Di Cataldo V, Triggiani L, Simoni N, Detti B, et al. Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis. *Radiol Med.* 2023;128:1423-8.
- [18] Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, et al. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups. *Lancet Oncol.* 2023;24:e331-e43.
- [19] Kaidar-Person O, Pfof A, Gentilini OD, Borisch B, Bosch A, Cardoso MJ, et al. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus. *EClinicalMedicine.* 2023;61:102085.
- [20] Oladeru OT, Dunn SA, Li J, Coles CE, Yamauchi C, Chang JS, et al. Looking Back: International Practice Patterns in Breast Radiation Oncology From a Case-Based Survey Across 54 Countries During the First Surge of the COVID-19 Pandemic. *JCO Glob Oncol.* 2023;9:e2300010.
- [21] Masi L, Doro R, Di Cataldo V, Francolini G, Zani M, Visani L, et al. Preoperative single fraction breast radiotherapy: Intra-fraction geometric uncertainties and dosimetric implications. *Phys Med.* 2023;112:102638.
- [22] Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skytta T, et al. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. *Radiother Oncol.* 2023;186:109805.
- [23] Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, et al. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. *Cancer Treat Rev.* 2023;119:102586.
- [24] Aznar MC, Carrasco de Fez P, Corradini S, Mast M, McNair H, Meattini I, et al. ESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy. *Radiother Oncol.* 2023;185:109734.
- [25] Nardone V, Meirson T, De Felice F, Meattini I. Genomic Profiling: Can We Rely on Retrospective Analysis to Drive Changes in Clinical Practice? *J Clin Oncol.* 2023;41:3957-8.
- [26] Kastora SL, Holmquist A, Valachis A, Rocco N, Meattini I, Somaiah N, et al. Outcomes of Different Quality of Life Assessment Modalities After Breast Cancer Therapy: A Network Meta-analysis. *JAMA Netw Open.* 2023;6:e2316878.

- [27] Di Lisa FS, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study. *Front Oncol.* 2023;13:1152123.
- [28] Aristei C, Kaidar-Person O, Boersma L, Leonardi MC, Offersen B, Franco P, et al. The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer. *Crit Rev Oncol Hematol.* 2023;187:104035.
- [29] Meattini I, de Oliveira Franco R, Salvestrini V, Hijal T. Partial Breast Irradiation. *Breast.* 2023;69:401-9.
- [30] Garreffa E, Meattini I, Coles CE, Agrawal A. Use of tumour bed boost radiotherapy in volume replacement oncoplastic breast surgery: A systematic review. *Crit Rev Oncol Hematol.* 2023;186:103996.
- [31] Fozza A, De Rose F, De Santis MC, Meattini I, Meduri B, D'Angelo E, et al. Technological advancements and future perspectives in breast cancer radiation therapy. *Expert Rev Anticancer Ther.* 2023;23:407-19.
- [32] Sars C, Sackey H, Frisell J, Dickman PW, Karlsson F, Kindts I, et al. Current clinical practice in the management of phyllodes tumors of the breast: an international cross-sectional study among surgeons and oncologists. *Breast Cancer Res Treat.* 2023;199:293-304.
- [33] Meattini I, Coles CE. Accumulating long-term evidence for partial breast irradiation. *Lancet Oncol.* 2023;24:198-9.
- [34] Franco P, De Felice F, Kaidar-Person O, Gabrys D, Marta GN, Banini M, et al. Equity, Diversity, and Inclusion in Radiation Oncology: A Bibliometric Analysis and Critical Review. *Int J Radiat Oncol Biol Phys.* 2023;116:232-45.
- [35] Franco P, De Felice F, Jagsi R, Nader Marta G, Kaidar-Person O, Gabrys D, et al. Breast cancer radiation therapy: A bibliometric analysis of the scientific literature. *Clin Transl Radiat Oncol.* 2023;39:100556.
- [36] Meattini I, Kim K, Livi L. Accelerated Partial Breast Irradiation: Florence Phase 3 Trial Experience and Future Perspectives. *Am J Clin Oncol.* 2023;46:10-5.
- [37] Poortmans P, Kaidar-Person O, Meattini I. The Global Community Stands with ASTRO's Experts in Protecting Women's Rights. *Int J Radiat Oncol Biol Phys.* 2023;115:836-8.
- [38] Visani L, Livi L, Ratosi I, Orazem M, Ribnikar D, Saieva C, et al. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. *Radiother Oncol.* 2022;177:40-5.
- [39] La Verde N, Damia G, Garrone O, Santini D, Fabi A, Ciccarese M, et al. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study. *Breast Cancer Res.* 2022;24:71.
- [40] Del Re M, Crucitta S, Omarini C, Bargagna I, Mongillo M, Palleschi M, et al. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. *Breast.* 2022;66:157-61.
- [41] Meattini I, Palumbo I, Becherini C, Borghesi S, Cucciarelli F, Dicuonzo S, et al. The Italian Association for Radiotherapy and Clinical Oncology (AIRO) position statements for postoperative breast cancer radiation therapy volume, dose, and fractionation. *Radiol Med.* 2022;127:1407-11.
- [42] Meattini I, Francolini G, Di Cataldo V, Visani L, Becherini C, Scoccimarro E, et al. Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894). *Clin Transl Radiat Oncol.* 2022;37:94-100.

- [43] Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermipas P, Baumert BG, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. *Lancet Oncol.* 2022;23:e469-e78.
- [44] Ciabattoni A, Gregucci F, De Rose F, Falivene S, Fozza A, Daidone A, et al. AIRO Breast Cancer Group Best Clinical Practice 2022 Update. *Tumori.* 2022;108:1-144.
- [45] Miglietta F, Visani L, Marini S, Griguolo G, Vernaci GM, Bottosso M, et al. Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? *Cancer Treat Rev.* 2022;110:102462.
- [46] Ciabattoni A, Gregucci F, D'Ermo G, Dolfi A, Cucciarelli F, Palumbo I, et al. Patterns of Care for Breast Radiotherapy in Italy: Breast IRRadiATA (Italian Repository of Radiotherapy dATA) Feasibility Study. *Cancers (Basel).* 2022;14.
- [47] Aristei C, Bolukbasi Y, Kaidar-Person O, Pfeffer R, Arenas M, Boersma LJ, et al. Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting. *Crit Rev Oncol Hematol.* 2022;177:103774.
- [48] Meattini I, Salvestrini V, Becherini C. Radiation therapy on the axilla after neoadjuvant chemotherapy. *Curr Opin Oncol.* 2022;34:647-52.
- [49] Fastner G, Krug D, Meattini I, Gruber G, Poortmans P. Expert Discussion: Hypofractionated Radiation Therapy - Standard for All Indications? *Breast Care (Basel).* 2022;17:224-31.
- [50] Desideri I, Lucidi S, Francolini G, Meattini I, Ciccone LP, Salvestrini V, et al. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA(R)) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833). *Med Oncol.* 2022;39:113.
- [51] Marrazzo L, Meattini I, Simontacchi G, Livi L, Pallotta S. Updates on the APBI-IMRT-Florence Trial (NCT02104895) Technique: From the Intensity Modulated Radiation Therapy Trial to the Volumetric Modulated Arc Therapy Clinical Practice. *Pract Radiat Oncol.* 2023;13:e28-e34.
- [52] Meattini I, Livi L, Lorito N, Becherini C, Bacci M, Visani L, et al. Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. *Cancer Treat Rev.* 2022;108:102417.
- [53] Marrazzo L, Redapi L, Zani M, Calusi S, Meattini I, Arilli C, et al. A semi-automatic planning technique for whole breast irradiation with tangential IMRT fields. *Phys Med.* 2022;98:122-30.
- [54] Coltelli L, Allegrini G, Orlandi P, Finale C, Fontana A, Masini LC, et al. A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients. *NPJ Breast Cancer.* 2022;8:33.
- [55] Loi M, Salvatore G, Sottili M, Calosi L, Desideri I, Becherini C, et al. Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer. *Clin Transl Oncol.* 2022;24:1395-402.
- [56] Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, et al. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. *Ther Adv Med Oncol.* 2021;13:17588359211059873.

- [57] Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, et al. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. *ESMO Open*. 2022;7:100381.
- [58] Marta GN, Riera R, Pacheco RL, Cabrera Martimbianco AL, Meattini I, Kaidar-Person O, et al. Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials. *Breast*. 2022;62:84-92.
- [59] Leonardi MC, Pepa M, Luraschi R, Vigorito S, Dicuonzo S, Isaksson LJ, et al. The dosimetric impact of axillary nodes contouring variability in breast cancer radiotherapy: An AIRO multi-institutional study. *Radiother Oncol*. 2022;168:113-20.
- [60] Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. *Lancet Oncol*. 2022;23:e21-e31.
- [61] Bernini M, Meattini I, Saieva C, Becherini C, Salvestrini V, Visani L, et al. Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy. *Breast Cancer*. 2022;29:302-13.
- [62] Desideri I, Francolini G, Ciccone LP, Stocchi G, Salvestrini V, Aquilano M, et al. Correction to: Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility. *Support Care Cancer*. 2022;30:1891-2.
- [63] Senkus E, Cardoso MJ, Kaidar-Person O, Lacko A, Meattini I, Poortmans P. De-escalation of axillary irradiation for early breast cancer - Has the time come? *Cancer Treat Rev*. 2021;101:102297.
- [64] Kaidar-Person O, Dahn HM, Nichol AM, Boersma LJ, de Ruyscher D, Meattini I, et al. A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. *Radiother Oncol*. 2021;164:115-21.
- [65] Francolini G, Ciccone LP, Di Cataldo V, Detti B, Simontacchi G, Loi M, et al. May Different Treatment Volumes and Technical Approaches Have an Impact on Second Malignancies Risk? *J Clin Oncol*. 2021;39:3762-3.
- [66] Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. *ESMO Open*. 2021;6:100231.
- [67] Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, et al. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. *JAMA Oncol*. 2021;7:1544-9.
- [68] Bernini M, Sordi S, Bembi N, Meattini I, De Benedetto D, Cucchiari JN, et al. Selective Denervation of Pectoralis Major Muscle Improves Cosmetic Outcome and Quality of Life in Retro-Pectoral Implant Based Breast Reconstruction. *Clin Breast Cancer*. 2022;22:60-6.
- [69] Kaidar-Person O, Offersen BV, Boersma L, Meattini I, Dodwell D, Wyld L, et al. Tricks and tips for target volume definition and delineation in breast cancer: Lessons learned from ESTRO breast courses. *Radiother Oncol*. 2021;162:185-94.

- [70] Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Sacca M, Gamucci T, et al. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. *Sci Rep.* 2021;11:13770.
- [71] Marta GN, Meattini I. Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial. *Lancet Oncol.* 2021;22:e297.
- [72] Meattini I, Becherini C, Bernini M, Bonzano E, Criscitiello C, De Rose F, et al. Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review. *Cancer Treat Rev.* 2021;99:102236.
- [73] Dahn HM, Boersma LJ, de Ruyscher D, Meattini I, Offersen BV, Pignol JP, et al. The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review. *Crit Rev Oncol Hematol.* 2021;163:103391.
- [74] Gentile P, Bernini M, Orzalesi L, Sordi S, Meattini I, Lessi F, et al. Titanium-coated polypropylene mesh as innovative bioactive material in conservatives mastectomies and pre-pectoral breast reconstruction. *Bioact Mater.* 2021;6:4640-53.
- [75] Leonardi MC, Pepa M, Gugliandolo SG, Luraschi R, Vigorito S, Rojas DP, et al. Geometric contour variation in clinical target volume of axillary lymph nodes in breast cancer radiotherapy: an AIRO multi-institutional study. *Br J Radiol.* 2021;94:20201177.
- [76] Krasniqi E, Pizzuti L, Valerio MR, Capomolla E, Botti C, Sanguineti G, et al. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. *Int J Med Sci.* 2021;18:2245-50.
- [77] Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, et al. Association of Breast Cancer Irradiation With Cardiac Toxic Effects: A Narrative Review. *JAMA Oncol.* 2021;7:924-32.
- [78] Francolini G, Desideri I, Stocchi G, Ciccone LP, Salvestrini V, Garlatti P, et al. Impact of COVID-19 on workload burden of a complex radiotherapy facility. *Radiol Med.* 2021;126:717-21.
- [79] Marino L, Lancellotta V, Franco P, Meattini I, Meduri B, Bernini M, et al. Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes response. Development of GRADE (Grades of recommendation, assessment, Development and Evaluation) recommendation by the Italian Association of radiation therapy and Clinical Oncology (AIRO). *Breast.* 2021;55:119-27.
- [80] Sardaro A, McDonald F, Bardoscia L, Lavrenkov K, Singh S, Ashley S, et al. Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study. *Front Oncol.* 2020;10:594590.
- [81] Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, et al. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. *Lancet Oncol.* 2021;22:e18-e28.
- [82] De Rose F, De Santis MC, Meduri B, Franzese C, Franceschini D, Franco P, et al. Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study). *J Cancer Res Clin Oncol.* 2021;147:2069-77.

- [83] Marta GN, Ramiah D, Kaidar-Person O, Kirby A, Coles C, Jaggi R, et al. The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report. *Clin Oncol (R Coll Radiol)*. 2021;33:322-30.
- [84] Benstead K, Lara PC, Eller Y, Engell-Noerregaard L, Eriksen JG, Gaye PM, et al. Clinical oncology module for the ESTRO core curriculum. *Radiother Oncol*. 2021;156:19-22.
- [85] Nuzzo M, Ursini LA, Patani F, Rosa C, Trignani M, M DIT, et al. Using the Bolus in Post-mastectomy Radiation Therapy (PMRT): A National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Breast Cancer Group. *Anticancer Res*. 2020;40:6505-11.
- [86] Marta GN, Coles C, Kaidar-Person O, Meattini I, Hijal T, Zissiadis Y, et al. The use of moderately hypofractionated post-operative radiation therapy for breast cancer in clinical practice: A critical review. *Crit Rev Oncol Hematol*. 2020;156:103090.
- [87] Jereczek-Fossa BA, Pepa M, Zaffaroni M, Marvaso G, Bruni A, Buglione di Monale EBM, et al. COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. *Radiother Oncol*. 2021;155:120-2.
- [88] Desideri I, Francolini G, Ciccone LP, Stocchi G, Salvestrini V, Aquilano M, et al. Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility. *Support Care Cancer*. 2021;29:2931-7.
- [89] Kaidar-Person O, Meattini I, Zippel D, Poortmans P. Apples and oranges: comparing partial breast irradiation techniques. *Rep Pract Oncol Radiother*. 2020;25:780-2.
- [90] Meattini I, Marrazzo L, Saieva C, Desideri I, Scotti V, Simontacchi G, et al. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. *J Clin Oncol*. 2020;38:4175-83.
- [91] Meattini I, Poortmans PMP, Marrazzo L, Desideri I, Brain E, Hamaker M, et al. Exclusive endocrine therapy or partial breast irradiation for women aged ≥ 70 years with luminal A-like early stage breast cancer (NCT04134598 - EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. *J Geriatr Oncol*. 2021;12:182-9.
- [92] Kaidar-Person O, Poortmans P, Offersen BV, Siesling S, Sklair-Levy M, Meattini I, et al. Spatial location of local recurrences after mastectomy: a systematic review. *Breast Cancer Res Treat*. 2020;183:263-73.
- [93] Loi M, Caini S, Scoccianti S, Bonomo P, De Vries K, Francolini G, et al. Stereotactic reirradiation for local failure of brain metastases following previous radiosurgery: Systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2020;153:103043.
- [94] Ratosa I, Orazem M, Scoccimarro E, Steinacher M, Dominici L, Aquilano M, et al. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer. *Clin Breast Cancer*. 2020;20:495-502.
- [95] De Santis MC, La Rocca E, Vitullo A, Meattini I, Livi L. Comment on "Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity". *Clin Breast Cancer*. 2020;20:e623-e4.
- [96] Arenas M, Selek U, Kaidar-Person O, Perrucci E, Montero Luis A, Boersma L, et al. The 2018 assisi think tank meeting on breast cancer: International expert panel white paper. *Crit Rev Oncol Hematol*. 2020;151:102967.

- [97] Jereczek-Fossa BA, Pepa M, Marvaso G, Bruni A, Buglione di Monale EBM, Catalano G, et al. COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). *Radiother Oncol.* 2020;149:89-93.
- [98] Loi M, Desideri I, Dominici L, Francolini G, Garlatti P, Ciccone LP, et al. Thermal Ablation versus SBRT in liver tumours: pros and cons. *Med Oncol.* 2020;37:52.
- [99] Meattini I, Franco P, Belgioia L, Boldrini L, Botticella A, De Santis MC, et al. Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists. *ESMO Open.* 2020;5.
- [100] Desideri I, Becherini C, Visani L, Stocchi G, Scoccimarro E, Mariotti M, et al. Outcome and prognostic factors for older patients undergoing radiosurgery for brain metastases. *J Geriatr Oncol.* 2020;11:1103-7.
- [101] Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. *Clin Oncol (R Coll Radiol).* 2020;32:279-81.
- [102] Lambertini M, Toss A, Passaro A, Criscitiello C, Cremolini C, Cardone C, et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. *ESMO Open.* 2020;5.
- [103] Meattini I, Andratschke N, Kirby AM, Sviri G, Offersen BV, Poortmans P, et al. Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. *Clin Transl Oncol.* 2020;22:1698-709.
- [104] Franco P, De Rose F, De Santis MC, Pasinetti N, Lancellotta V, Meduri B, et al. Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine. *Clin Transl Radiat Oncol.* 2020;21:112-9.
- [105] Gregucci F, Fozza A, Falivene S, Smaniotto D, Morra A, Daidone A, et al. Present clinical practice of breast cancer radiotherapy in Italy: a nationwide survey by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) Breast Group. *Radiol Med.* 2020;125:674-82.
- [106] Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, et al. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. *J Cell Physiol.* 2020;235:7900-10.
- [107] Poortmans PMP, Takanen S, Marta GN, Meattini I, Kaidar-Person O. Winter is over: The use of Artificial Intelligence to individualise radiation therapy for breast cancer. *Breast.* 2020;49:194-200.
- [108] Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. *Lancet Oncol.* 2020;21:e18-e28.
- [109] Meattini I, Poortmans P, Kirova Y, Saieva C, Visani L, Salvestrini V, et al. Hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-centre comparative study. *Acta Oncol.* 2020;59:188-95.
- [110] Taffurelli M, Pellegrini A, Meattini I, Orzalesi L, Tinterri C, Roncella M, et al. Corrigendum to "Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of breast surgeons (ANISC)" [Breast 2019 56-60]. *Breast.* 2019;48:101.

- [111] Meattini I, De Santis MC, De Rose F, Desideri I, Franco P, Kaidar-Person O, et al. Local Treatment of the Axilla in Early Breast Cancer: So Many Questions, Still Few Answers. *Clin Oncol (R Coll Radiol)*. 2020;32:e37-e8.
- [112] De Rose F, Cozzi L, Meattini I, Fogliata A, Franceschini D, Franzese C, et al. The Potential Role of Intensity-modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study. *Clin Oncol (R Coll Radiol)*. 2020;32:26-34.
- [113] Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, et al. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. *Int J Cancer*. 2020;146:1917-29.
- [114] Corradini S, Krug D, Meattini I, Fastner G, Matuschek C, Cutuli B. Challenges in Radiotherapy. *Breast Care (Basel)*. 2019;14:152-8.
- [115] Corradini S, Krug D, Meattini I, Matuschek C, Bolke E, Francolini G, et al. Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. *Crit Rev Oncol Hematol*. 2019;141:102-11.
- [116] Kaidar-Person O, Vrou Offersen B, Hol S, Arenas M, Aristei C, Bourcier C, et al. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. *Radiother Oncol*. 2019;137:159-66.
- [117] Montero-Luis A, Aristei C, Meattini I, Arenas M, Boersma L, Bourcier C, et al. The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. *Crit Rev Oncol Hematol*. 2019;138:207-13.
- [118] Meattini I, Lambertini M, Desideri I, De Caluwe A, Kaidar-Person O, Livi L. Radiation therapy for young women with early breast cancer: Current state of the art. *Crit Rev Oncol Hematol*. 2019;137:143-53.
- [119] Kaidar-Person O, Meattini I, Poortmans PMP. "Between Uncertainties and Overtreatment". *Int J Radiat Oncol Biol Phys*. 2019;104:15-6.
- [120] Belkacemi Y, Majdoul S, Tsoutsou PP, Abouegylah M, Kaidar-Person O, Meattini I, et al. Is Postoperative Breast Radiation Therapy Safe in Patients With Scleroderma? *Int J Radiat Oncol Biol Phys*. 2019;104:10-1.
- [121] Taffurelli M, Pellegrini A, Meattini I, Orzalesi L, Tinterri C, Roncella M, et al. Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC). *Breast*. 2019;45:56-60.
- [122] Marrazzo L, Meattini I, Arilli C, Calusi S, Casati M, Talamonti C, et al. Auto-planning for VMAT accelerated partial breast irradiation. *Radiother Oncol*. 2019;132:85-92.
- [123] Desideri I, Francolini G, Carta GA, Di Cataldo V, Masi L, Meattini I, et al. Efficacy and Tolerability of CyberKnife Stereotactic Robotic Radiotherapy for Primary or Secondary Orbital Lesions: A Single-Center Retrospective Experience. *Technol Cancer Res Treat*. 2019;18:1533033818818561.
- [124] Arcangeli S, Jereczek-Fossa BA, Alongi F, Aristei C, Becherini C, Belgioia L, et al. Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. *Crit Rev Oncol Hematol*. 2019;134:104-19.
- [125] Arcangeli S, Jereczek-Fossa BA, Alongi F, Aristei C, Becherini C, Belgioia L, et al. Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy. *Crit Rev Oncol Hematol*. 2019;134:87-103.

- [126] Tanini S, Fisher AD, Meattini I, Bianchi S, Ristori J, Maggi M, et al. Testosterone and Breast Cancer in Transmen: Case Reports, Review of the Literature, and Clinical Observation. *Clin Breast Cancer*. 2019;19:e271-e5.
- [127] Livi L, Scotti V, Desideri I, Saieva C, Cecchini S, Francolini G, et al. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. *Eur J Cancer*. 2019;108:100-10.
- [128] Becherini C, Meattini I, Livi L, Garlatti P, Desideri I, Scotti V, et al. External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial. *Tumori*. 2019;105:205-9.
- [129] Francolini G, Desideri I, Meattini I, Becherini C, Terziani F, Olmetto E, et al. Assessment of a guideline-based heart substructures delineation in left-sided breast cancer patients undergoing adjuvant radiotherapy : Quality assessment within a randomized phase III trial testing a cardioprotective treatment strategy (SAFE-2014). *Strahlenther Onkol*. 2019;195:43-51.
- [130] Meattini I, Pasinetti N, Meduri B, De Rose F, De Santis MC, Franco P, et al. A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). *Radiother Oncol*. 2019;131:208-14.
- [131] Mangoni M, Sottili M, Salvatore G, Campanacci D, Scoccianti G, Beltrami G, et al. Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors? *Radiol Med*. 2019;124:282-9.